FRANKFURT, Nov 15 (Reuters) - GPC Biotech is cutting 44 percent of its workforce, or 103 staff, the German biotech company said on Thursday, after its key prostate cancer drug hope satraplatin failed in a clinical trial.
FRANKFURT, Nov 15 (Reuters) - GPC Biotech is cutting 44 percent of its workforce, or 103 staff, the German biotech company said on Thursday, after its key prostate cancer drug hope satraplatin failed in a clinical trial.
